When do you think this stock will start to move higher? How low short term do you think we are going?
(1) " Lynparza is currently the only FDA-approved PARP inhibitor, but when Clovis Oncology's Rucaparib is released to the public, Lynparza may see its sales suffer. "
(2) " Market expansion could allow both drugs to thrive, allowing Lynparza to reach, or even surpass, its predicted potential."
(3) "......the soon-to-be-approved Rucaparib has proven to be superior and may decrease Lynparza's value as an asset. "
(4) "Threatening that is Clovis Oncology's (NASDAQ:CLVS) Rucaparib. Rucaparib has recently finished phase 2 studies, and is scheduled to file its new drug application in 2016. It has received recognition from the FDA as a breakthrough therapy - something Lynparza failed to acquire - and for all intents and purposes, is Lynparza's superior."
(5) "The breakthrough therapy designates priority treatment and an expedited review. Another reason for Rucaparib's superiority is that phase 2 study results have shown the drug boasting a much higher response rate in patients than Lynparza. Rucaparib measured at 82% versus Lynparza's 34%."
(6) "I have no doubt it[rucparib] will be considered first in class upon its release to the public."
A more complete statement, "Flynn added shares of Clovis Oncology Inc (NASDAQ: CLVS) to Goldman Sach's "Americas Conviction List" given the assumption that Rocilentinib (Roci) will be approved for a subset of lung cancer in the first quarter 2016. In the near-term, the company is "on track" to complete its regulatory filing Monday morning.
Flynn added that he is "confident" the company can successfully move Roci into the front-line setting, where a Phase 2/3 trial is ongoing. In addition, the analyst is projecting peak sales of $2 billion in 2018 ($2.8 billion unadjusted), which assumes a probability of success in the 70 to 90 percent range."
Of note here is the expectation that the NDA for rociletinib should be completed this week. Also, with expanded studies the "subset" of patients approved for Roci should be a multiple of the current subset.
Clovis Oncology Inc. (NASDAQ: CLVS) was reiterated as Buy at Goldman Sachs, but the firm added it to the prized Conviction Buy List with a $110 price target (versus an $87.06 close).
Peak revenues for rociletinib alone should exceed three billion dollars. 50,000 patients at
$60,000 per year would reach that number. The world wide number of patients with non small cell lung cancer who might benefit from rociletinib probably exceeds 300,000 per year. Do the numbers and come up with a very large amount of revenue.
With regard to rucaparib my guess is that its peak revenues also will exceed three billion dollars.
All IMO of course.
More so now with the RCPT takeout by CELG. CLVS is the next one! Should trade up to $95 by the end of the week
Sentiment: Strong Buy
maybe they are going to use it to purchased a small company? maybe they realized they need more money for research than they thought they needed? I respect your answers and am happy you own the stock.
Thank you. That was a nice explanation. So would you feel good if you bought the stock at 78? Also since this is thinly traded doe you feel these institutions are waited for much better days?
This type of secondary offering underwritten by the likes of JP Morgan and Credit Suisse et alii is sold to institutions who are clients of these respective firms. Since Fidelity was also involved, to a lesser degree some individuals might have received some stock. The price for all is $78 per share. It is highly doubtful that any of this offering was sold on the open market. The fact that the underwriters fully subscribed to the over allotment reflects on the demand.
Once the institutions received indications that they own the stock, they are free to sell any or all of their stock on the open market.
I would like to know how they are sold. I don't know if they are sold to private people or on the open market. Or to somebody who then slowly leaks it out into the open market
what are you talking about?. do you know what a secondary is and how the shares are sold during the syndicate period? the answer is no!
The comments are as true now as two days ago. Wall Street's surprise...stock dropped 10% in two days. During last conference call it was stated that the company had the funds to support the trials planned and cash on hand indicated this. At no time during that CC did the company hint at the immediate need to raise cash. I wonder why?? Lastly, if you object to my hoping that the secondary funds will be used wisely, just check out Moly Corp, Aone, Vivus, and so many others to understand that desire. I'm long Clvs but expect management to be transparent and honest. cheers